Related Experiment Video
Updated: Oct 28, 2025
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.7K
Attenuated Postprandial GLP-1 Response in Parkinson's Disease
Richard A Manfready1, Phillip A Engen2, Leo Verhagen Metman3
1Division of Digestive Diseases and Nutrition, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.
Frontiers in Neuroscience
|July 19, 2021
Summary
Parkinson's disease patients exhibit reduced glucagon-like peptide 1 (GLP-1) secretion after meals, potentially linked to gut microbiota changes. This finding supports further research into GLP-1 therapies for Parkinson's disease.
Area of Science:
- Neuroscience
- Endocrinology
- Gastroenterology
Background:
- Glucagon-like peptide 1 (GLP-1) demonstrates neuroprotective effects in Parkinson's disease (PD) animal models.
- GLP-1 receptor agonists show clinical benefits in human PD patients.
- Intestinal microbiota produce short-chain fatty acids (SCFAs) that stimulate GLP-1 secretion.
Purpose of the Study:
- To investigate postprandial GLP-1 secretion in Parkinson's disease patients.
- To explore the relationship between GLP-1 levels and PD characteristics.
- To assess the impact of altered gut microbiota on GLP-1 secretion in PD.
Main Methods:
- Meal tolerance tests were conducted to measure GLP-1 levels.
- GLP-1 levels were compared between PD patients and household controls.
- Correlation analyses were performed between GLP-1 levels and PD severity, motor function, and disease duration.
Main Results:
- Parkinson's disease patients showed diminished postprandial GLP-1 secretion compared to controls.
- Peak GLP-1 levels did not correlate with PD disease severity.
- Peak GLP-1 levels did not correlate with motor function or disease duration.
Conclusions:
- PD patients exhibit impaired GLP-1 secretion, possibly due to altered gut microbiota.
- These findings provide a rationale for investigating GLP-1-based therapies for PD.
- Further research is warranted to elucidate GLP-1's role in PD pathogenesis.
Related Concept Videos
01:24Parkinson's Disease: Treatment
569
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
569
01:24Glucagon-like Receptor Agonists
498
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
498
01:15Parkinson's Disease: Overview
991
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
991
01:23Dipeptidyl Peptidase 4 Inhibitors
303
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
303
01:37Neural Regulation
40.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.6K
01:06Oral Hypoglycemic Agents: Glinides
320
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
320